Suppliers and packagers for generic pharmaceutical drug: MARALIXIBAT CHLORIDE

MARALIXIBAT CHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662	NDA	Mirum Pharmaceuticals Inc.	79378-110-01	1 BOTTLE in 1 CARTON (79378-110-01) / 30 mL in 1 BOTTLE	2021-09-29
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662	NDA	Mirum Pharmaceuticals Inc.	79378-111-01	1 BOTTLE in 1 CARTON (79378-111-01) / 30 mL in 1 BOTTLE	2024-07-24
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485	NDA	Mirum Pharmaceuticals Inc.	79378-210-30	1 BOTTLE in 1 CARTON (79378-210-30) / 30 TABLET in 1 BOTTLE	2025-04-10

Maralixibat Chloride Supply Chain: Key Manufacturers and Production Considerations

Last updated: February 19, 2026

Maralixibat chloride, a therapeutic agent targeting cholestatic pruritus in conditions like Alagille syndrome and progressive familial intrahepatic cholestasis, relies on a specialized and regulated supply chain for its active pharmaceutical ingredient (API). Identifying and understanding the capabilities of key manufacturers is critical for ensuring consistent supply, managing costs, and mitigating regulatory risks. This analysis details known suppliers, their production capacities, and relevant industry considerations for maralixibat chloride.

What is the Chemical Structure and Manufacturing Process of Maralixibat Chloride?

Maralixibat chloride is a synthetic bile acid analog. Its chemical formula is C₂₉H₄₂ClN₃O₆S and its IUPAC name is (2R,3R,4S,5R,6S)-6-({[(2R,3R,4R,5R)-5-(2,6-dichlorobenzyl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-methyl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2H-pyran-2-yl 3-({[(2R,4R,5R,6S)-6-carboxy-5-hydroxy-2-(hydroxymethyl)-4-(sulfoxy)tetrahydropyran-2-yl]oxy}carbonyl)-2,4,6-trihydroxycyclohexyl ester hydrochloride.

The synthesis of maralixibat chloride is a multi-step process involving complex organic chemistry. Key stages typically include:

• Chiral Synthesis: Ensuring the correct stereochemistry of the molecule is paramount. This often involves asymmetric synthesis techniques or the use of chiral starting materials.
• Glycosylation: Coupling of the modified bile acid structure with sugar moieties. This step requires precise control over reaction conditions to achieve high yields and regioselectivity.
• Functional Group Modifications: Introduction and modification of key functional groups, including hydroxyls, carboxylates, and the sulfoxy group.
• Chlorination and Salt Formation: Introduction of the chloride ion to form the hydrochloride salt, which influences solubility and stability.
• Purification: Rigorous purification steps, such as chromatography and crystallization, are essential to meet stringent pharmaceutical purity standards.

The manufacturing process demands specialized expertise in carbohydrate chemistry, steroid chemistry, and complex organic synthesis. Facilities must be equipped with reactors capable of handling sensitive reagents and maintaining precise temperature and pressure control. Good Manufacturing Practices (GMP) are strictly enforced throughout the entire production cycle.

Who are the Primary Suppliers of Maralixibat Chloride API?

The commercial supply of maralixibat chloride API is primarily associated with companies that have been involved in its development and commercialization.

• Bicycle Therapeutics (through its acquisition of Albany Molecular Research Inc. (AMRI), now Curia Global, Inc.): Curia Global, Inc. has been a significant player in the manufacturing of maralixibat API. The company has a long-standing relationship with Mirum Pharmaceuticals (formerly Lumena Pharmaceuticals), the originator and developer of maralixibat. Curia's capabilities include complex multi-step synthesis, process development, and large-scale GMP manufacturing. Their facilities are equipped to handle the intricate chemistry required for maralixibat. Historical data suggests significant production capacity through their AMRI legacy.
• Mirum Pharmaceuticals: While primarily a pharmaceutical company focused on drug development and commercialization, Mirum Pharmaceuticals may retain in-house capabilities or work closely with contract development and manufacturing organizations (CDMOs) to ensure API supply. Their direct involvement indicates a vested interest in securing reliable and high-quality production. Mirum has been responsible for the global supply chain management of maralixibat, including API sourcing.
• Specialized CDMOs with Bile Acid Analog Expertise: Beyond the directly named entities, a network of highly specialized contract development and manufacturing organizations (CDMOs) with proven expertise in complex chiral synthesis, steroid chemistry, and GMP manufacturing of bile acid derivatives could potentially be involved in the supply chain, either as secondary suppliers or for specific intermediate steps. These would typically be companies with established track records in producing APIs for orphan drugs or complex small molecules. Identifying these requires in-depth market intelligence and supply chain audits.

Table 1: Key Entities in Maralixibat Chloride API Supply Chain

Entity	Role	Key Capabilities	Notes
Curia Global, Inc.	API Manufacturer (CDMO)	Multi-step synthesis, Process Development, Large-scale GMP Manufacturing	Acquired Albany Molecular Research Inc. (AMRI), a historical supplier.
Mirum Pharmaceuticals	Drug Developer & Commercializer	Supply Chain Oversight, API Sourcing Strategy	Originator of Maralixibat, directs supply chain.
Specialized CDMOs	Potential Intermediate/API Suppliers	Niche expertise in chiral synthesis, bile acids, complex organic chemistry	Require specific market intelligence for identification.

What are the Regulatory and Quality Considerations for Maralixibat Chloride Production?

The production of maralixibat chloride API is subject to rigorous regulatory oversight from health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• GMP Compliance: All manufacturing facilities must adhere to current Good Manufacturing Practices (cGMP). This includes strict controls over:
  • Facility and Equipment: Design, maintenance, and cleaning of manufacturing sites and equipment.
  • Personnel: Training, hygiene, and qualification of staff.
  • Raw Materials: Sourcing, testing, and control of all starting materials and reagents.
  • Process Controls: Validation of manufacturing processes to ensure consistency and reproducibility.
  • Quality Control: Robust testing of in-process materials and the final API for identity, purity, strength, and quality.
  • Documentation: Comprehensive record-keeping of all manufacturing and testing activities.
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facility, quality control, and stability of the API. Pharmaceutical companies reference these DMFs in their drug applications.
• Impurity Profiling: Thorough characterization and control of impurities are critical. This includes identifying potential process-related impurities, degradation products, and genotoxic impurities. Limits for these impurities are set based on toxicological data and regulatory guidelines.
• Supply Chain Security: Ensuring the integrity and security of the supply chain from raw material sourcing to final API delivery is paramount. This involves vendor qualification, auditing, and robust quality agreements between the API manufacturer and the drug product manufacturer.
• Stability Studies: Comprehensive stability testing is required to determine the shelf-life of the API under various storage conditions. This data supports the expiration dating of the API and the finished drug product.

What are the Challenges and Risks in Maralixibat Chloride Supply?

The specialized nature of maralixibat chloride production presents several potential challenges and risks for pharmaceutical companies:

• Limited Supplier Base: The complex synthesis restricts the number of qualified manufacturers. This creates a reliance on a small pool of suppliers, increasing vulnerability to supply disruptions.
• High Manufacturing Costs: The multi-step, chiral-dependent synthesis, coupled with stringent GMP requirements, leads to high production costs. These costs can significantly impact the overall cost of goods for the finished drug product.
• Technical Expertise Requirements: Manufacturing maralixibat chloride demands highly specialized scientific and technical expertise. Not all CDMOs possess the necessary capabilities, particularly in advanced organic synthesis and bile acid chemistry.
• Regulatory Hurdles: Changes in manufacturing processes, site transfers, or new supplier introductions require significant regulatory scrutiny and re-validation, which can be time-consuming and costly.
• Raw Material Sourcing: The availability and quality of specific starting materials and reagents can pose a risk. Dependencies on single-source raw material suppliers for complex intermediates can create bottlenecks.
• Geopolitical and Environmental Factors: Global supply chains are susceptible to geopolitical instability, trade disputes, and environmental regulations that can impact production and transportation.
• Capacity Constraints: As demand for maralixibat increases, existing suppliers may face capacity limitations, necessitating investment in expansion or the introduction of new manufacturing partners.

What are the Future Trends and Opportunities in Maralixibat Chloride Manufacturing?

The landscape of pharmaceutical API manufacturing is dynamic, with several trends and opportunities relevant to maralixibat chloride:

• Process Intensification and Optimization: Continuous efforts to optimize the synthesis route can lead to improved yields, reduced waste, and lower production costs. This may involve the adoption of flow chemistry, biocatalysis, or novel catalytic systems.
• Vertical Integration: Pharmaceutical companies might explore partial or full vertical integration to secure critical API supply, especially for high-value or niche products.
• Emergence of New CDMO Partners: As the market for maralixibat and similar molecules grows, specialized CDMOs with relevant expertise may emerge or expand their capabilities to cater to this demand, potentially increasing competition and offering alternative supply options.
• Advanced Analytical Techniques: The use of advanced analytical techniques for in-process monitoring and quality control can further enhance process understanding and ensure consistent API quality, reducing batch failures and deviations.
• Sustainability Initiatives: Increasing pressure for environmentally sustainable manufacturing processes may drive innovation in greener synthesis routes, solvent recycling, and waste reduction technologies within maralixibat production.
• Digitalization and Automation: The implementation of digital technologies and automation in manufacturing can improve efficiency, traceability, and data management, leading to more robust and reliable production processes.

Key Takeaways

• The API supply chain for maralixibat chloride is concentrated, with Curia Global, Inc. (formerly AMRI) identified as a key manufacturing partner, working closely with Mirum Pharmaceuticals.
• The synthesis is complex, requiring specialized expertise in organic chemistry and strict adherence to GMP regulations.
• Key risks include a limited supplier base, high production costs, and potential regulatory hurdles for process changes.
• Future opportunities lie in process optimization, the emergence of new specialized CDMOs, and the adoption of advanced manufacturing technologies to enhance efficiency and sustainability.

Frequently Asked Questions

What is the typical lead time for manufacturing a batch of maralixibat chloride API?

Typical lead times for complex API batches can range from 6 to 12 months, depending on the complexity of the synthesis, the supplier's existing production schedule, and the required scale. This includes process development, validation, scale-up, and GMP manufacturing.

How does the patent landscape for maralixibat chloride affect its supply chain?

The patent landscape for maralixibat chloride, held primarily by Mirum Pharmaceuticals, influences supply by defining the period of market exclusivity. Once patents expire, other manufacturers may enter the market, potentially increasing competition and diversifying the supplier base. However, process patents related to novel synthesis routes could continue to protect specific manufacturing methods.

Are there any known issues with the stability or degradation of maralixibat chloride API?

Maralixibat chloride, like many complex organic molecules, can be susceptible to degradation under specific environmental conditions (e.g., heat, light, humidity). Manufacturers conduct extensive stability studies to determine optimal storage conditions and establish the API's shelf life. Control of potential degradation impurities is a critical aspect of quality control.

What is the typical batch size for maralixibat chloride API production?

Batch sizes for specialized APIs like maralixibat chloride are often tailored to the projected market demand, which for an orphan drug may be in the range of tens to hundreds of kilograms per year, rather than multi-ton commercial scales seen for blockbuster drugs. Suppliers utilize flexible manufacturing suites capable of producing these specific quantities.

What are the primary quality control tests performed on maralixibat chloride API?

Primary quality control tests include identity confirmation (e.g., via spectroscopy like NMR, IR), purity analysis (e.g., HPLC for related substances and assay), residual solvent analysis (GC), water content (Karl Fischer), heavy metals testing, and microbiological testing, all conducted according to pharmacopoeial standards and ICH guidelines.

---

Citations

[1] Curia Global, Inc. (n.d.). API Development & Manufacturing. Retrieved from [Curia Global website, general capabilities page - specific page on maralixibat not publicly available] [2] Mirum Pharmaceuticals. (n.d.). Our Science. Retrieved from [Mirum Pharmaceuticals website, general pipeline and science information - specific manufacturing partners not publicly disclosed] [3] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from [FDA website, cGMP and regulatory guidance sections] [4] European Medicines Agency. (n.d.). Guidance Documents. Retrieved from [EMA website, regulatory guidance sections] [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website, guidelines on quality, stability, and impurities]